Custom-Made immune cells target advanced cancers in new trial
NCT ID NCT07275853
Summary
This is a first-in-human study to test the safety and early signs of effectiveness of a new personalized gene therapy called KXV01 for people with advanced solid tumors. The therapy involves collecting a patient's own tumor cells, identifying unique markers, and then using a modified virus to teach the patient's immune cells to target those markers. The study will enroll about 30 adults whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.